argenx (ARGX)

• Market cap: $46B
• 1 day: -2.39%
• 5 days: -3.98%
• 1 month: 11.04%
• 3 months: 35.81%
• 6 months: 19.56%
• Year to date: 18.41%
• 1 year: 40.62%
• 5 years: 200.4%
• 10 years: 3,092.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Employees: 1,639

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

126% more call options, than puts

Call options by funds: $270M | Put options by funds: $120M

22% more repeat investments, than reductions

Existing positions increased: 177 | Existing positions reduced: 145

8% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 59

2% less funds holding

Funds holding: 441 [Q1] → 433 (-8) [Q2]

2.29% less ownership

Funds ownership: 54.89% [Q1] → 52.59% (-2.29%) [Q2]

6% less funds holding in top 10

Funds holding in top 10: 18 [Q1] → 17 (-1) [Q2]

10% less capital invested

Capital invested by funds: $19.7B [Q1] → $17.7B (-$2.03B) [Q2]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $715
• Avg. target: $839
• High target: $1,070

10 analyst ratings

• positive: 10 100%
• neutral: 0 0%
• negative: 0 0%

Truist Securities Joon Lee	$918	Buy Maintained	15 Sep 2025
B of A Securities Tazeen Ahmad	$887	Buy Maintained	2 Sep 2025
Piper Sandler Allison Bratzel	$820	Overweight Maintained	26 Aug 2025
RBC Capital Luca Issi	$850	Outperform Initiated	25 Aug 2025
JP Morgan James Gordon	$830	Overweight Maintained	4 Aug 2025